Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
217 studies found for:    S1105
Show Display Options
Rank Status Study
1 Active, not recruiting S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
Condition: Breast Cancer
Intervention: Behavioral: Text message reminder
2 Recruiting S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma
Condition: Stomach Neoplasms
Intervention: Drug: S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium
3 Recruiting Boston Scientific Post Market S-ICD Registry
Condition: Tachycardia, Ventricular
Intervention: Device: S-ICD System
4 Active, not recruiting A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma, B-Cell, Lymphoma, Follicular
Interventions: Drug: DCDS4501A;   Drug: DCDT2980S;   Drug: rituximab [MabThera/Rituxan]
5 Terminated A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
Condition: Diabetic Neuropathies
Interventions: Drug: Placebo;   Drug: [S,S]-Reboxetine
6 Active, not recruiting Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Condition: Moderate to Severe Palmoplantar Psoriasis
Interventions: Biological: secukinumab 150 mg;   Biological: secukinumab 300 mg;   Biological: Placebo
7 Completed
Has Results
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Condition: Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
8 Active, not recruiting 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Drug: Secukinumab (75 mg);   Drug: Secukinumab (150 mg);   Drug: Placebo
9 Completed
Has Results
Study of Adalimumab in Patients With Axial Spondyloarthritis
Condition: Axial Spondyloarthritis
Interventions: Biological: Adalimumab;   Biological: Placebo;   Biological: Open-label Adalimumab
10 Recruiting The Effects of Propranolol on Fear of Wisdom Tooth Removal
Condition: Dental Anxiety
Intervention: Drug: Propranolol
11 Completed Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Conditions: Acquired Bleeding Disorder;   Intracerebral Haemorrhage
Intervention: Drug: activated recombinant human factor VII
12 Active, not recruiting The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 1
Interventions: Drug: liraglutide;   Drug: placebo
13 Completed A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Conditions: Stomach Neoplasms;   Esophageal Neoplasms
Interventions: Drug: BMS-833923;   Drug: Cisplatin;   Drug: Capecitabine
14 Recruiting Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: adalimumab;   Drug: prednisone;   Drug: azathioprine
15 Recruiting A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors
Condition: Ulcerative Colitis
Interventions: Drug: etrolizumab;   Drug: infliximab;   Other: placebo (injection);   Other: placebo (IV)
16 Recruiting Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Condition: Atherosclerosis
Interventions: Drug: Canakinumab;   Drug: Placebo
17 Active, not recruiting Chronic Plaque Psoriasis (Ps) Registry
Condition: Chronic Plaque Psoriasis
Intervention:
18 Completed Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Conditions: Acquired Bleeding Disorder;   Intracerebral Haemorrhage
Intervention: Drug: activated recombinant human factor VII
19 Unknown  Serial Echocardiography After Subarachnoid Hemorrhage
Conditions: Subarachnoid Hemorrhage;   Myocardial Stunning;   Takotsubo Cardiomyopathy
Intervention:
20 Recruiting 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Biological: Secukinumab;   Biological: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years